Literature DB >> 15896650

Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.

Timothy C Zhu1, Jarod C Finlay, Stephen M Hahn.   

Abstract

It is desirable to quantify the distribution of the light fluence rate, the optical properties, the drug concentration, and the tissue oxygenation for photodynamic therapy (PDT) of prostate cancer. We have developed an integrated system to determine these quantities before and after PDT treatment using motorized probes. The optical properties (absorption (micro(a)), transport scattering (micro(s'), and effective attenuation (micro(eff)) coefficients) of cancerous human prostate were measured in-vivo using interstitial isotropic detectors. Measurements were made at 732 nm before and after motexafin lutetium (MLu) mediated PDT at different locations along each catheter. The light fluence rate distribution was also measured along the catheters during PDT. Diffuse absorption spectroscopy measurement using a white light source allows extrapolation of the distribution of oxygen saturation StO2, total blood volume ([Hb]t), and MLu concentration. The distribution of drug concentration was also studied using fluorescence from a single optical fiber, and was found to be in good agreement with the values determined by absorption spectroscopy. This study shows significant inter- and intra-prostatic variations in the tissue optical properties and MLu drug distribution, suggesting that a real-time dosimetry measurement and feedback system for monitoring these values during treatment should be considered in future PDT studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15896650      PMCID: PMC4470428          DOI: 10.1016/j.jphotobiol.2004.09.013

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  31 in total

1.  Modeling the output ratio in air for megavoltage photon beams.

Authors:  T C Zhu; B E Bjärngard; Y Xiao; C J Yang
Journal:  Med Phys       Date:  2001-06       Impact factor: 4.071

2.  Calibration of isotropic light dosimetry probes based on scattering bulbs in clear media.

Authors:  J P Marijnissen; W M Star
Journal:  Phys Med Biol       Date:  1996-07       Impact factor: 3.609

3.  Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin.

Authors:  S C Chang; G Buonaccorsi; A MacRobert; S G Bown
Journal:  Int J Cancer       Date:  1996-08-07       Impact factor: 7.396

4.  Expression of optical diffusion coefficient in high-absorption turbid media.

Authors:  T Nakai; G Nishimura; K Yamamoto; M Tamura
Journal:  Phys Med Biol       Date:  1997-12       Impact factor: 3.609

5.  Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.

Authors:  Timothy C Zhu; Andreea Dimofte; Jarod C Finlay; Diana Stripp; Theresa Busch; Jeremy Miles; Richard Whittington; S Bruce Malkowicz; Zelig Tochner; Eli Glatstein; Stephen M Hahn
Journal:  Photochem Photobiol       Date:  2005 Jan-Feb       Impact factor: 3.421

6.  In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.

Authors:  Michael Solonenko; Rex Cheung; Theresa M Busch; Alex Kachur; Gregory M Griffin; Theodore Vulcan; Timothy C Zhu; Hsing-Wen Wang; Stephen M Hahn; A G Yodh
Journal:  Phys Med Biol       Date:  2002-03-21       Impact factor: 3.609

7.  In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.

Authors:  Timothy C Zhu; Stephen M Hahn; Amy S Kapatkin; Andreea Dimofte; Carmen E Rodriguez; Teodor G Vulcan; Eli Glatstein; R Alex Hsi
Journal:  Photochem Photobiol       Date:  2003-01       Impact factor: 3.421

8.  Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study.

Authors:  Timothy R Nathan; Douglas E Whitelaw; Stanley C Chang; William R Lees; Paul M Ripley; Heather Payne; Linda Jones; M Constance Parkinson; Mark Emberton; Alison R Gillams; Anthony R Mundy; Stephen G Bown
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

Review 9.  Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out.

Authors:  A V D'Amico; C N Coleman
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

10.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

View more
  73 in total

1.  Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption.

Authors:  Tiancheng Liu; Lisa Y Wu; Clifford E Berkman
Journal:  Cancer Lett       Date:  2010-05-08       Impact factor: 8.679

Review 2.  A review of in-vivo optical properties of human tissues and its impact on PDT.

Authors:  Julia L Sandell; Timothy C Zhu
Journal:  J Biophotonics       Date:  2011-11       Impact factor: 3.207

3.  Depth profiling of photothermal compound concentrations using phase sensitive optical coherence tomography.

Authors:  Guangying Guan; Roberto Reif; Zhihong Huang; Ruikang K Wang
Journal:  J Biomed Opt       Date:  2011-12       Impact factor: 3.170

Review 4.  Glycosylated Porphyrins, Phthalocyanines, and Other Porphyrinoids for Diagnostics and Therapeutics.

Authors:  Sunaina Singh; Amit Aggarwal; N V S Dinesh K Bhupathiraju; Gianluca Arianna; Kirran Tiwari; Charles Michael Drain
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

5.  Treatment planning using tailored and standard cylindrical light diffusers for photodynamic therapy of the prostate.

Authors:  Augusto Rendon; J Christopher Beck; Lothar Lilge
Journal:  Phys Med Biol       Date:  2008-02-05       Impact factor: 3.609

6.  Three-dimensional fluence rate measurement and data acquisition system for minimally invasive light therapies.

Authors:  Benjamin Lai; Maxim Loshchenov; Alexander Douplik; Rob Rusnov; Marcos Jimenez-Davila; George Netchev; Lothar Lilge
Journal:  Rev Sci Instrum       Date:  2009-04       Impact factor: 1.523

Review 7.  Hierarchical clustering method to improve transrectal ultrasound-guided diffuse optical tomography for prostate cancer imaging.

Authors:  Venkaiah C Kavuri; Hanli Liu
Journal:  Acad Radiol       Date:  2014-02       Impact factor: 3.173

8.  Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.

Authors:  N Betrouni; S Boukris; F Benzaghou
Journal:  Lasers Med Sci       Date:  2017-06-01       Impact factor: 3.161

9.  A heterogeneous algorithm for PDT dose optimization for prostate.

Authors:  Martin D Altschuler; Timothy C Zhu; Yida Hu; Jarod C Finlay; Andreea Dimofte; Ken Wang; Jun Li; Keith Cengel; S B Malkowicz; Stephen M Hahn
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2009-02-18

10.  Choline PET for monitoring early tumor response to photodynamic therapy.

Authors:  Baowei Fei; Hesheng Wang; Chunying Wu; Song-mao Chiu
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.